Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to Grb2 or Crk1
AssigneeBoard of Regents, The University of Texas System
InventorsGabriel Lopez-Berestein, Ana M. Tari, Ralph B. Arlinghaus
Life of this patent
Estimating the term…
Abstract
The present invention provides novel compositions and methods for use in the treatment of cancer, specifically, in the treatment of chronic myelogenous leukemia (CML). The compositions contain antisense oligonucleotides that hybridize to Grb2 and Crkl nucleic acids, the gene products of which are known to interact with the tumorigenic protein bcr-abl. Used alone, in conjunction with each other, and even in conjunction with antisense oligonucleotides directed to bcr-abl nucleic acids, these compositions inhibit the proliferation of CML cancer cells.
Claims28
A composition comprising a polynucleotide that hybridizes to a Grb2-encoding polynucleotide.
A composition comprising a polynucleotide that hybridizes to a Crkl-encoding polynucleotide.
A composition comprising (i) a polynucleotide that hybridizes to a Grb2-encoding polynucleotide or (ii) a polynucleotide that hybridizes to a Crkl-encoding polynucleotide.
A composition comprising an expression construct that encodes a first polynucleotide that hybridizes to a Grb2-encoding polynucleotide, wherein said first polynucleotide is under the control of a promoter that is active in eukaryotic cells.
A composition comprising an expression construct that encodes a first polynucleotide that hybridizes to a Crkl-encoding polynucleotide, wherein said first polynucleotide is under the control of a promoter that is active in eukaryotic cells.
A method for inhibiting proliferation of a cancer cell comprising contacting said cancer cell with a composition comprising at least (i) a polynucleotide that hybridizes to a Grb2 nucleic acid or (ii) a polynucleotide that hybridizes to a Crkl nucleic acid.
The method of claim 28, wherein said composition is administered three times per week for eight weeks.
Dependencies are inferred from the claim text.